Current Value
$2.431 Year Return
Current Value
$2.431 Year Return
Yahoo
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, with non-segmental vitiligo being
Yahoo
As the S&P 500 hovers near record highs and treasury yields drop following retail sales data, investors are keeping a close eye on the broader U.S. market trends. Penny stocks, often associated with smaller or newer companies, remain an intriguing investment area despite their vintage name. These stocks can offer a blend of affordability and growth potential when backed by solid financials, making them worth considering for those seeking opportunities in this unique segment of the market.
Yahoo
Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund Edesa’s CXCL10 antibody program through the end of fiscal 2026 TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has sold, in a private placement
Yahoo
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, with non-segmental vitiligo being
Yahoo
As the Dow Jones Industrial Average experiences a prolonged losing streak and investors closely watch Federal Reserve decisions, market participants are seeking opportunities that might weather such volatility. Penny stocks, though often seen as speculative, can still hold potential when they exhibit strong financial fundamentals. These smaller or newer companies may offer unique value propositions and growth prospects that could appeal to investors looking for under-the-radar opportunities...
Yahoo
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business. During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05 (paridiprubart), to a U.S. government-funded study investigating novel
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DNOW | 44.79% | $1.83B | +14.94% | 0.00% |
CRSR | 41.98% | $938.45M | -25.97% | 0.00% |
CROX | 40.22% | $6.25B | -19.62% | 0.00% |
ENTA | 39.34% | $113.06M | -68.28% | 0.00% |
IRDM | 38.52% | $2.94B | +5.38% | 2.17% |
MGM | 36.91% | $8.78B | -34.22% | 0.00% |
GEL | 36.08% | $1.95B | +36.53% | 4.20% |
GRAL | 34.41% | $886.02M | +91.36% | 0.00% |
LECO | 33.02% | $10.91B | -22.10% | 1.62% |
AUR | 32.54% | $12.46B | +137.09% | 0.00% |
BROS | 32.32% | $7.28B | +91.53% | 0.00% |
GEHC | 31.02% | $36.29B | -10.86% | 0.18% |
AEIS | 30.17% | $3.64B | -2.74% | 0.48% |
PLMR | 30.17% | $3.78B | +71.49% | 0.00% |
EEFT | 29.88% | $4.73B | +1.15% | 0.00% |
PZZA | 29.46% | $1.37B | -36.03% | 4.47% |
PGY | 29.21% | $835.81M | +10.34% | 0.00% |
ASPS | 28.53% | $61.75M | -59.01% | 0.00% |
MYGN | 28.38% | $803.52M | -56.65% | 0.00% |
ANAB | 28.30% | $581.75M | -8.45% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
USDU | -15.22% | $206.96M | 0.5% |
UUP | -13.08% | $325.79M | 0.77% |
VIXY | -11.09% | $195.31M | 0.85% |
KMLM | -10.48% | $218.49M | 0.9% |
GBIL | -9.39% | $6.30B | 0.12% |
USFR | -9.37% | $18.53B | 0.15% |
XONE | -8.18% | $631.21M | 0.03% |
TFLO | -8.18% | $6.75B | 0.15% |
BTAL | -7.85% | $416.76M | 1.43% |
TAIL | -7.81% | $87.65M | 0.59% |
JMST | -7.10% | $3.54B | 0.18% |
KRBN | -7.03% | $175.08M | 0.85% |
BILS | -6.48% | $3.67B | 0.1356% |
SHYM | -6.14% | $318.40M | 0.35% |
BSMW | -5.76% | $101.29M | 0.18% |
TBLL | -5.68% | $2.13B | 0.08% |
BUXX | -5.66% | $234.79M | 0.25% |
UNG | -5.29% | $397.59M | 1.06% |
EQLS | -4.99% | $4.80M | 1% |
BILZ | -4.31% | $734.41M | 0.14% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 26.91% | $292.67M | 0% |
QQA | 25.04% | $187.77M | 0% |
BTC | 24.54% | $3.28B | 0.15% |
PTH | 23.69% | $107.91M | 0.6% |
IHF | 23.51% | $669.92M | 0.4% |
FFTY | 23.45% | $63.06M | 0.8% |
CPRJ | 23.36% | $48.38M | 0.69% |
BLCN | 22.06% | $41.94M | 0.68% |
PREF | 21.97% | $1.15B | 0.55% |
INDA | 21.60% | $8.84B | 0.62% |
INDY | 21.49% | $640.27M | 0.89% |
QETH | 21.14% | $14.36M | 0.25% |
EZET | 21.01% | $22.46M | 0% |
ETHA | 21.00% | $2.27B | 0.25% |
FLIN | 20.97% | $1.76B | 0.19% |
ETHV | 20.95% | $87.97M | 0% |
CETH | 20.88% | $10.49M | 0% |
MXI | 20.78% | $229.91M | 0.42% |
NUHY | 20.77% | $99.31M | 0.31% |
ETH | 20.76% | $1.29B | 0% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
WST | -56.23% | $16.01B | -42.79% | 0.38% |
TTD | -43.68% | $27.93B | -35.24% | 0.00% |
PEGA | -31.16% | $6.20B | +16.23% | 0.18% |
GXO | -25.35% | $4.79B | -21.71% | 0.00% |
SLF | -24.92% | $33.67B | +10.14% | 4.06% |
BTI | -23.53% | $88.37B | +33.72% | 7.17% |
TNET | -22.75% | $3.94B | -40.45% | 1.35% |
FSLY | -21.78% | $940.60M | -47.95% | 0.00% |
PBF | -20.46% | $2.26B | -68.10% | 6.14% |
CGNX | -18.71% | $5.18B | -25.04% | 1.15% |
HBI | -17.84% | $2.10B | +15.09% | 0.00% |
H | -17.67% | $12.00B | -20.78% | 0.52% |
IRMD | -17.29% | $681.53M | +26.68% | 1.21% |
IRM | -16.49% | $25.88B | +11.22% | 3.45% |
UL | -15.74% | $150.02B | +22.41% | 2.99% |
ZBRA | -14.32% | $14.78B | -1.77% | 0.00% |
ASPN | -12.30% | $527.11M | -62.37% | 0.00% |
CHH | -11.75% | $6.26B | +12.70% | 0.90% |
STNG | -11.59% | $1.87B | -48.89% | 4.57% |
MSBI | -11.12% | $369.39M | -29.03% | 7.75% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNMA | -0.06% | $355.69M | 0.1% |
STXT | -0.11% | $134.22M | 0.49% |
IBTH | -0.13% | $1.51B | 0.07% |
AGZ | -0.14% | $644.13M | 0.2% |
CORN | 0.16% | $52.17M | 0.2% |
LONZ | -0.17% | $936.29M | 0.63% |
FLDR | 0.20% | $775.30M | 0.15% |
IBMP | -0.22% | $513.49M | 0.18% |
BSJP | -0.22% | $991.97M | 0.43% |
CLOA | 0.23% | $783.46M | 0.2% |
MMIT | -0.24% | $834.61M | 0.3% |
CMF | -0.29% | $3.77B | 0.08% |
EWZS | 0.33% | $128.27M | 0.6% |
AGZD | -0.35% | $134.05M | 0.23% |
UTWO | 0.38% | $377.39M | 0.15% |
DBMF | 0.41% | $1.21B | 0.85% |
BSCR | 0.42% | $3.25B | 0.1% |
HEDJ | 0.44% | $1.69B | 0.58% |
IBMN | -0.45% | $472.63M | 0.18% |
DBB | -0.49% | $122.94M | 0.77% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RPRX | <0.01% | $13.55B | +8.61% | 2.68% |
CHCT | <0.01% | $513.79M | -28.99% | 10.25% |
ITRN | -0.02% | $766.38M | +32.43% | 4.80% |
LNT | -0.02% | $16.55B | +30.41% | 2.98% |
LITB | -0.02% | $41.93M | -46.48% | 0.00% |
BOX | -0.03% | $4.53B | +13.12% | 0.00% |
NBR | -0.03% | $408.70M | -52.58% | 0.00% |
HOLX | -0.04% | $13.59B | -21.89% | 0.00% |
SPSC | -0.05% | $5.20B | -21.29% | 0.00% |
ADM | -0.06% | $23.03B | -23.43% | 4.19% |
NOG | -0.06% | $3.03B | -25.26% | 6.39% |
ALB | -0.06% | $8.49B | -43.94% | 2.42% |
NXDT | -0.08% | $174.95M | -34.50% | 15.94% |
SHO | 0.08% | $1.90B | -13.93% | 4.12% |
CRM | 0.08% | $260.95B | -10.89% | 0.47% |
ACN | -0.08% | $198.03B | -4.80% | 1.83% |
ARRY | -0.09% | $750.95M | -65.69% | 0.00% |
GNRC | 0.10% | $7.64B | -0.06% | 0.00% |
SYM | -0.10% | $2.37B | -50.64% | 0.00% |
MSCI | 0.11% | $44.70B | +6.66% | 1.20% |